Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy. [electronic resource]
- Liver international : official journal of the International Association for the Study of the Liver Oct 2011
- 1359-65 p. digital
Publication Type: Journal Article; Multicenter Study
1478-3231
10.1111/j.1478-3231.2011.02571.x doi
Aged Amino Acid Substitution Antiviral Agents--therapeutic use Biopsy Chi-Square Distribution Drug Resistance, Viral--genetics Drug Therapy, Combination Female Genotype Hepacivirus--drug effects Hepatitis C, Chronic--complications Humans Interferon alpha-2 Interferon-alpha--therapeutic use Interferons Interleukins--genetics Japan Liver Cirrhosis--drug therapy Logistic Models Male Middle Aged Mutation Patient Selection Phenotype Polyethylene Glycols--therapeutic use Polymorphism, Single Nucleotide RNA, Viral--blood Recombinant Proteins--therapeutic use Ribavirin--therapeutic use Risk Assessment Risk Factors Time Factors Treatment Outcome Viral Core Proteins--genetics Viral Load Viral Nonstructural Proteins--genetics